NASDAQ:APTO - Aptose Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.94 -0.22 (-3.57 %) (As of 04/1/2020 03:44 AM ET) Add Compare Today's Range$5.83Now: $5.94▼$6.4750-Day Range$4.74MA: $7.06▼$9.0052-Week Range$1.81Now: $5.94▼$9.25Volume498,468 shsAverage Volume1.09 million shsMarket Capitalization$453.04 millionP/E RatioN/ADividend YieldN/ABeta1.63 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APTO Previous Symbol CUSIPN/A CIK882361 Webhttp://www.aptose.com/ Phone858-926-2730Debt Debt-to-Equity RatioN/A Current Ratio17.83 Quick Ratio17.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book4.83Profitability EPS (Most Recent Fiscal Year)($0.52) Net Income$-26,280,000.00 Net MarginsN/A Return on Equity-61.63% Return on Assets-55.07%Miscellaneous EmployeesN/A Outstanding Shares76,270,000Market Cap$453.04 million Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive APTO News and Ratings via Email Sign-up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:APTO Rates by TradingView Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions How has Aptose Biosciences' stock been impacted by COVID-19 (Coronavirus)? Aptose Biosciences' stock was trading at $5.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, APTO shares have increased by 1.7% and is now trading at $5.94. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aptose Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptose Biosciences. When is Aptose Biosciences' next earnings date? Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Aptose Biosciences. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) issued its quarterly earnings results on Tuesday, March, 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. View Aptose Biosciences' earnings history. What price target have analysts set for APTO? 5 Wall Street analysts have issued 1-year price objectives for Aptose Biosciences' stock. Their forecasts range from $9.00 to $16.00. On average, they anticipate Aptose Biosciences' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 102.0% from the stock's current price. View analysts' price targets for Aptose Biosciences. Has Aptose Biosciences been receiving favorable news coverage? Media headlines about APTO stock have trended very negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aptose Biosciences earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAptose Biosciences. Are investors shorting Aptose Biosciences? Aptose Biosciences saw a decline in short interest in the month of March. As of March 13th, there was short interest totaling 367,400 shares, a decline of 5.7% from the February 27th total of 389,800 shares. Based on an average daily volume of 924,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.5% of the company's shares are sold short. View Aptose Biosciences' Current Options Chain. Who are some of Aptose Biosciences' key competitors? Some companies that are related to Aptose Biosciences include Fate Therapeutics (FATE), Cortexyme (CRTX), Regenxbio (RGNX), Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), Coherus Biosciences (CHRS), Editas Medicine (EDIT), I-Mab (BDTX), Beam Therapeutics (BEAM), NanoString Technologies (NSTG), Adverum Biotechnologies (ADVM), Oyster Point Pharma (OYST), Sangamo Therapeutics (SGMO) and Orchard Therapeutics (ORTX). What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), Micron Technology (MU), Viking Therapeutics (VKTX) and AT&T (T). Who are Aptose Biosciences' key executives? Aptose Biosciences' management team includes the following people: Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell, Chief Medical Officer (Age 73)Mr. Peter Murray, Director of Clinical Devel. What is Aptose Biosciences' stock symbol? Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO." How do I buy shares of Aptose Biosciences? Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aptose Biosciences' stock price today? One share of APTO stock can currently be purchased for approximately $5.94. How big of a company is Aptose Biosciences? Aptose Biosciences has a market capitalization of $453.04 million. The biotechnology company earns $-26,280,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. View additional information about Aptose Biosciences. What is Aptose Biosciences' official website? The official website for Aptose Biosciences is http://www.aptose.com/. How can I contact Aptose Biosciences? Aptose Biosciences' mailing address is 12770 HIGH BLUFF DRIVE SUITE 120, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-926-2730 or via email at [email protected] MarketBeat Community Rating for Aptose Biosciences (NASDAQ APTO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 328 (Vote Outperform)Underperform Votes: 274 (Vote Underperform)Total Votes: 602MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe APTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/1/2020 by MarketBeat.com StaffFeatured Article: What’s a Black Swan?
